With FDA Approval for Advanced Lymphoma, Second CAR T-Cell Therapy Moves to the Clinic

One month after approving the first CAR T-cell therapy for cancer, FDA has approved a second such therapy. The treatment, axicabtagene ciloleucel (Yescarta™), was approved for some patients with advanced non-Hodgkin lymphoma.

from Cancer via ola Kala on Inoreader http://ift.tt/2z7UUvO
via IFTTT